Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
NARLAL2
Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®
- NCT02354274 ↗
- Recruiting
- Olfred Hansen
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on NARLAL2 (locally advanced non-small cell lung cancer; tests no drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NARLAL2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 14 posts on X |
The trial
ClinicalTrials.gov- Official title
- Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®
- Phase
- Phase not applicable
- Status
- Recruiting
- Conditions
- NSCLC
- Interventions
- Escalated: Inhomogeneous dose plan; Standard: Homogeneous dose plan
- Arms
- Standard: Homogeneous dose plan · Active comparator
- Escalation: Inhomogeneous dose plan · Experimental
- Enrollment
- 330 (estimated)
- Primary outcomes
- Locoregional control (Tumor recurrency is assessed by scheduled CT (of the thorax and upper abdomen)
- Sponsor
- Olfred Hansen with Odense University Hospital, Aarhus University Hospital, Copenhagen University Hospital, Rigshospitalet, Vejle Hospital, Naestved Hospital, Aalborg University Hospital, Herlev Hospital
- Start
- Jan 2015
- Primary completion
- Oct 2029 (estimated)
- Results posted
- No
- Registry record
- NCT02354274 · updated Apr 25, 2022
Publications
linked from the registry- Schytte T, Knap MM, Kristiansen C, Appelt AL, Khalil A, Peucelle C, Lutz CM, Moller DS, Sande EPS, Sundby F, Persson G, Schmidt H, Land LH, Rogg L, Pohl M, Lund MD, Nielsen M, Levin N, Hansen O, Thing RS, Borissova S, Halvorsen T, Nielsen TB, Hansen TS, Haakensen VD, Ottosson W, Brink C, Hoffmann L. Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial. J Clin Oncol. 2025 Jun 10;43(17):1972-1983. doi: 10.1200/JCO-24-01386. Epub 2025 Apr 18. PubMed 40249893